Only 12% of patients with solid tumors are served by immunotherapy drugs available today.

We are helping cancer patients spend time on what matters most by targeting untapped metabolic signaling pathways to restore anti-tumor immunity and provide better outcomes for patients.

We are helping cancer patients spend time on what matters most by targeting untapped metabolic signaling pathways to restore anti-tumor immunity and provide better outcomes for patients.